DE10003835A1 - Formulierungen bei Dehydratationszuständen - Google Patents
Formulierungen bei DehydratationszuständenInfo
- Publication number
- DE10003835A1 DE10003835A1 DE10003835A DE10003835A DE10003835A1 DE 10003835 A1 DE10003835 A1 DE 10003835A1 DE 10003835 A DE10003835 A DE 10003835A DE 10003835 A DE10003835 A DE 10003835A DE 10003835 A1 DE10003835 A1 DE 10003835A1
- Authority
- DE
- Germany
- Prior art keywords
- creatine
- formulations
- dehydration
- formulations according
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 238000009472 formulation Methods 0.000 title claims abstract description 18
- 230000018044 dehydration Effects 0.000 title claims abstract description 17
- 238000006297 dehydration reaction Methods 0.000 title claims abstract description 17
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims abstract description 45
- 229960003624 creatine Drugs 0.000 claims abstract description 20
- 239000006046 creatine Substances 0.000 claims abstract description 20
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 8
- MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960004826 creatine monohydrate Drugs 0.000 claims abstract description 6
- 239000012530 fluid Substances 0.000 claims abstract description 6
- DLNGCCQFGNSBOP-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;2-oxopropanoic acid Chemical compound CC(=O)C(O)=O.NC(=N)N(C)CC(O)=O DLNGCCQFGNSBOP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 4
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 4
- 239000003978 infusion fluid Substances 0.000 claims abstract description 4
- 229940072107 ascorbate Drugs 0.000 claims abstract description 3
- 239000002775 capsule Substances 0.000 claims abstract description 3
- 239000000843 powder Substances 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims abstract description 3
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 208000005156 Dehydration Diseases 0.000 abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 11
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 206010016807 Fluid retention Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 241000881711 Acipenser sturio Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000007911 effervescent powder Substances 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10003835A DE10003835A1 (de) | 2000-01-28 | 2000-01-28 | Formulierungen bei Dehydratationszuständen |
| PCT/EP2001/000863 WO2001054676A2 (fr) | 2000-01-28 | 2001-01-26 | Formulations destinees a des etats de deshydratation |
| AU2001244108A AU2001244108A1 (en) | 2000-01-28 | 2001-01-26 | Formulations for states of dehydration |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10003835A DE10003835A1 (de) | 2000-01-28 | 2000-01-28 | Formulierungen bei Dehydratationszuständen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10003835A1 true DE10003835A1 (de) | 2001-08-16 |
Family
ID=7629123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10003835A Withdrawn DE10003835A1 (de) | 2000-01-28 | 2000-01-28 | Formulierungen bei Dehydratationszuständen |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2001244108A1 (fr) |
| DE (1) | DE10003835A1 (fr) |
| WO (1) | WO2001054676A2 (fr) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10215007A1 (de) * | 2002-04-05 | 2003-10-16 | Degussa Bioactives Deutschland | Verwendung von Kreatinpyruvat zur Steigerung der Ausdauer bei hochintensiven körperlichen Intervallbelastungen |
| DE102004009962A1 (de) * | 2004-03-01 | 2005-09-22 | Degussa Ag | Verwendung von Guanidin-Verbindungen als physiologisches Stärkungsmittel in Form von Nahrungsergänzungsmitteln, Futtermittelzusätzen, in kosmetischen Zubereitungen und als Pflanzenstärkungsmittel |
| US8501810B2 (en) | 2004-06-09 | 2013-08-06 | Alzchem Trostberg Gmbh | Guanidino acetic acid used as an animal food additive |
| WO2019185408A1 (fr) | 2018-03-27 | 2019-10-03 | Evonik Degussa Gmbh | Utilisation de l'acide guanidinoacétique et/ou de la créatine en aquaculture |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030212136A1 (en) | 2001-09-14 | 2003-11-13 | Vennerstrom Jonathan L. | Creatine ester pronutrient compounds and formulations |
| EP1688139A1 (fr) * | 2000-09-14 | 2006-08-09 | Board of Regents of the University of Nebraska | Composés et formulations d'esters de créatine |
| DE102007004781A1 (de) | 2007-01-31 | 2008-08-07 | Alzchem Trostberg Gmbh | Verwendung von Guanidinoessigsäure(-Salzen) zur Herstellung eines gesundheitsfördernden Mittels |
| US9233099B2 (en) | 2012-01-11 | 2016-01-12 | University Of Cincinnati | Methods of treating cognitive dysfunction by modulating brain energy metabolism |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991014435A1 (fr) * | 1990-03-19 | 1991-10-03 | Brigham And Women's Hospital | Traitement de troubles osmotiques a l'aide d'osmolytes organiques |
| US5397786A (en) * | 1993-01-08 | 1995-03-14 | Simone; Charles B. | Rehydration drink |
| PL330279A1 (en) * | 1996-12-20 | 1999-05-10 | Sueddeutsche Kalkstickstoff | Creatin-pivivolates and method of obtaining them |
| AU6726098A (en) * | 1997-02-26 | 1998-09-18 | Skw Trostberg Aktiengesellschaft | Creatine-ascorbates, production process |
| DE19929994A1 (de) * | 1998-07-09 | 2000-01-13 | Sueddeutsche Kalkstickstoff | Verwendung von Kreatin zur Behandlung von Dystrophien und Atrophien der Skelettmuskulatur |
| DE19841385A1 (de) * | 1998-09-10 | 2000-03-16 | Sueddeutsche Kalkstickstoff | Verwendung von Kreatin und/oder Kreatin-derivaten als Feuchthaltemittel in kosmetischen Zubereitungen |
| AU6153200A (en) * | 1999-06-30 | 2001-01-22 | Skw Trostberg Aktiengesellschaft | Use of creatine and/or creatine derivatives for treating feelings of ill-health in women |
-
2000
- 2000-01-28 DE DE10003835A patent/DE10003835A1/de not_active Withdrawn
-
2001
- 2001-01-26 AU AU2001244108A patent/AU2001244108A1/en not_active Abandoned
- 2001-01-26 WO PCT/EP2001/000863 patent/WO2001054676A2/fr active Application Filing
Non-Patent Citations (1)
| Title |
|---|
| Diss. Abstr. Int., B 1999, 59(12), 6247 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10215007A1 (de) * | 2002-04-05 | 2003-10-16 | Degussa Bioactives Deutschland | Verwendung von Kreatinpyruvat zur Steigerung der Ausdauer bei hochintensiven körperlichen Intervallbelastungen |
| DE102004009962A1 (de) * | 2004-03-01 | 2005-09-22 | Degussa Ag | Verwendung von Guanidin-Verbindungen als physiologisches Stärkungsmittel in Form von Nahrungsergänzungsmitteln, Futtermittelzusätzen, in kosmetischen Zubereitungen und als Pflanzenstärkungsmittel |
| US8501810B2 (en) | 2004-06-09 | 2013-08-06 | Alzchem Trostberg Gmbh | Guanidino acetic acid used as an animal food additive |
| WO2019185408A1 (fr) | 2018-03-27 | 2019-10-03 | Evonik Degussa Gmbh | Utilisation de l'acide guanidinoacétique et/ou de la créatine en aquaculture |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001054676A3 (fr) | 2002-05-16 |
| WO2001054676A2 (fr) | 2001-08-02 |
| AU2001244108A1 (en) | 2001-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1692729C3 (de) | Verwendung einer Salzmischung als Würzsalz | |
| DE60027197T2 (de) | Verwendung von ribose zur verhinderung von krämpfen und muskelkater | |
| AT503219A1 (de) | Kombinationspräparat zur verbesserung der samenqualität | |
| DE60125191T2 (de) | Zusammensetzungen und methoden zur verbesserung der kardiovaskulären funktion | |
| DE10003835A1 (de) | Formulierungen bei Dehydratationszuständen | |
| DE2414593A1 (de) | Arzneimittel und verfahren zu seiner herstellung | |
| Thornton | Influence of exogenous ascorbic acid on calcium and phosphorus metabolism in the chick | |
| DE4413839C1 (de) | Kombinationspräparat | |
| DE19910682B4 (de) | Verwendung eines Kombinationspräparates zur Therapie einer Fibrat-induzierten Hyperhomocysteinämie | |
| EP2931258B1 (fr) | Compositions et solutions pour le lavage intestinal | |
| DE3445253A1 (de) | Nephrologisch-urologisches arzneimittel | |
| CA2617253C (fr) | Composes synergiques pour accelerer la reparation des tissus | |
| DE102004052882A1 (de) | Nahrungsergänzungsmittel und Herstellungsverfahren dafür | |
| WO2003084351A1 (fr) | Utilisation de creatine pyruvate pour augmenter l'endurance lors de sollicitations corporelles intermittentes de grande intensite | |
| DE102005046892A1 (de) | Zusammensetzung aus planzlichem Material und Verwendung derselben zur Herstellung eines Medikaments zur Behandlung von Übergewicht, Fettleibigkeit und Fettsucht | |
| EP0673913B1 (fr) | Sels de citrates de calcium et d'alcalins ainsi que leur utilisation comme médicaments | |
| DE60020888T2 (de) | Zusatz aus kräutern zur behandlung von kognitiven störungen aufgrund von östrogenverlust | |
| DE102004039983A1 (de) | Pharmazeutische oder kosmetische Zusammensetzung | |
| EP2072046A1 (fr) | Utilisation d'une préparation comprenant un hydrocarbonate destiné à la prévention ou au traitement des maladies cardio-vasculaires, du diabète, de l'ostéoporose et de la déficience rénale chronique | |
| DE102004008375B4 (de) | Verwendung von physiologisch verträglichen Ascorbatverbindungen in Kombination mit einem Sympathomimetikum als lokales Therapeutikum für Schleimhäute der Atemwege | |
| EP0291751B1 (fr) | Préparation pharmaceutique constituée par un mélange | |
| DE102005031363A1 (de) | Mittel mit Anti-Aging-Effekt | |
| DE10160485A1 (de) | Verwendung von Kreatin und/oder einem seiner physiologisch geeigneten Derivate zur Prävention oder Linderung von nicht krankheitsbedingten Beeinträchtigungen und/oder Störungen der Muskelfunktion | |
| DE19929994A1 (de) | Verwendung von Kreatin zur Behandlung von Dystrophien und Atrophien der Skelettmuskulatur | |
| EP1563743B1 (fr) | Composition comprenant une substance contenant de la caféine, en particulier guarana |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8139 | Disposal/non-payment of the annual fee |